ClinicalTrials.gg

Program

emaretamig

Its studies are mostly in Adenocarcinoma, led by Astellas Pharma.

Furthest: phase 3, since Jun 23, 20263 company-led studies, 3 open or runningNext primary completion: Jan 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma33 open or runningphase 3since Jun 23, 2026May 5, 2022Jan 31, 2028phase 1 · NCT07024615

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2022First study: phase 1 study in AdenocarcinomaFirst studyNCT05365581 · 398 planned · United States, China, France and more
  2. Jun 9, 2025Phase 1 study in Pancreatic Ductal AdenocarcinomaNCT07024615 · 25 planned · United States
  3. Jun 23, 2026Phase 3 study in AdenocarcinomaPhase 3 reachedNCT07673887 · 570 planned · United States, China, Japan and more

Ahead

  1. Jan 31, 2028Primary completion: phase 1 study in Pancreatic Ductal AdenocarcinomaNCT07024615
  2. May 31, 2028Primary completion: phase 1 study in AdenocarcinomaNCT05365581
  3. Feb 28, 2031Primary completion: phase 3 study in AdenocarcinomaNCT07673887

TargetBeta

CD3E →CLDN18 →read by rule
“A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07673887Adenocarcinoma · United States, China, Japan and more3RecruitingFeb 28, 2031570
NCT07024615Pancreatic Ductal Adenocarcinoma · United States1RecruitingJan 31, 202825
NCT05365581Adenocarcinoma · United States, China, France and more1RecruitingMay 31, 2028398

How it is read

Names in the registry

  • “ASP2138”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.